# Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma

> **NCT05102721** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vaccinex Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Avelumab and Pepinemab

## Key facts

- **NCT ID:** NCT05102721
- **Lead sponsor:** Vaccinex Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-10
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05102721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05102721, "Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05102721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*